2 weeks Ago By ABMN Staff
Scientech Research LLC acquired a new position in shares of Bio-Rad Laboratories, Inc. ( NYSE:BIO – Free Report ) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 4,343 shares of the medical research company’s stock, valued at approximately $1,186,000.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Capital Advisors Ltd. LLC grew its position in shares of Bio-Rad Laboratories by 193.
8% during the 2nd quarter. Capital Advisors Ltd. LLC now owns 94 shares of the medical research company’s stock worth $26,000 after buying an additional 62 shares during the period.
Sound Income Strategies LLC acquired a new stake in Bio-Rad Laboratories in the first quarter worth $38,000. EntryPoint Capital LLC acquired a new stake in Bio-Rad Laboratories in the first quarter worth $51,000. Headlands Technologies LLC bought a new position in shares of Bio-Rad Laboratories during the second quarter worth $51,000.
Finally, Parallel Advisors LLC grew its holdings in shares of Bio-Rad Laboratories by 36.8% in the 4th quarter. Parallel Advisors LLC now owns 171 shares of the medical research company’s stock valued at $55,000 after buying an additional 46 shares during the period.
Institutional investors own 65.24% of the company’s stock. Insider Activity at Bio-Rad Laboratories In related news, EVP James Barry sold 623 shares of the business’s stock in a transaction on Wednesday, September 4th.
The shares were sold at an average price of $330.49, for a total transaction of $205,895.27.
Following the transaction, the executive vice president now directly owns 147 shares in the company, valued at $48,582.03. The sale was disclosed in a filing with the SEC, which is available through this link .
In other Bio-Rad Laboratories news, COO Andrew J. Last sold 3,000 shares of the company’s stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $329.
94, for a total value of $989,820.00. Following the sale, the chief operating officer now owns 7,559 shares in the company, valued at $2,494,016.
46. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link . Also, EVP James Barry sold 623 shares of Bio-Rad Laboratories stock in a transaction that occurred on Wednesday, September 4th.
The stock was sold at an average price of $330.49, for a total value of $205,895.27.
Following the transaction, the executive vice president now owns 147 shares of the company’s stock, valued at $48,582.03. The disclosure for this sale can be found here .
17.06% of the stock is owned by insiders. Wall Street Analyst Weigh In Get Our Latest Report on BIO Bio-Rad Laboratories Stock Down 0.
1 % BIO stock opened at $331.71 on Friday. The company has a debt-to-equity ratio of 0.
18, a current ratio of 6.28 and a quick ratio of 4.63.
The stock has a market capitalization of $9.46 billion, a P/E ratio of -32.02 and a beta of 0.
95. Bio-Rad Laboratories, Inc. has a fifty-two week low of $261.
59 and a fifty-two week high of $366.30. The business has a 50-day moving average of $325.
80 and a 200-day moving average of $307.44. Bio-Rad Laboratories ( NYSE:BIO – Get Free Report ) last released its quarterly earnings results on Thursday, August 1st.
The medical research company reported $3.11 earnings per share for the quarter, topping analysts’ consensus estimates of $2.12 by $0.
99. Bio-Rad Laboratories had a positive return on equity of 3.77% and a negative net margin of 51.
73%. The firm had revenue of $638.50 million during the quarter, compared to the consensus estimate of $645.
79 million. During the same quarter in the prior year, the firm posted $3.00 EPS.
The business’s revenue was down 6.3% on a year-over-year basis. On average, sell-side analysts anticipate that Bio-Rad Laboratories, Inc.
will post 10.31 earnings per share for the current fiscal year. Bio-Rad Laboratories Company Profile ( Free Report ) Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America.
It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets. Featured Stories Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. ( NYSE:BIO – Free Report ). Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.
com's FREE daily email newsletter ..
